{"id":333,"date":"2009-07-22T20:58:29","date_gmt":"2009-07-22T19:58:29","guid":{"rendered":"http:\/\/moomango.co.uk\/ttfa\/?page_id=333"},"modified":"2009-07-22T20:58:29","modified_gmt":"2009-07-22T19:58:29","slug":"risk-of-opportunistic-infections-by-cd4-count-and-effect-of-arv-treatment","status":"publish","type":"page","link":"https:\/\/i-base.info\/ttfa\/learning-resources\/risk-of-opportunistic-infections-by-cd4-count-and-effect-of-arv-treatment\/","title":{"rendered":"Risk of opportunistic infections by CD4 count and effect of ARV treatment"},"content":{"rendered":"<p>This table summarises the OIs and coinfections discussed in section 5,      together with the impact of ARV treatment.<\/p>\n<p><strong>Table: OIs and coinfections and the impact of ARVs<\/strong><\/p>\n<table border=\"0\">\n<tbody>\n<tr>\n<th>Opportunistic infection<\/th>\n<th>CD4 risk level (cells\/mm<sup>3<\/sup>)<\/th>\n<th>Prophylaxis<\/th>\n<th>Protection returns after ARVs increase CD4 count<\/th>\n<\/tr>\n<tr>\n<td>Cancer: sarcoma and lymphoma<\/td>\n<td>Varies. Can be any CD4. NHL usually 200 or less<\/td>\n<td>None<\/td>\n<td>Varies depending on lymphoma. KS can resolve on ARVs alone.<\/td>\n<\/tr>\n<tr>\n<td>Malaria<\/td>\n<td>Any CD4<\/td>\n<td>No*<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Hepatitis B and C<\/td>\n<td>Any CD4<\/td>\n<td>None for hepatitis C. Vaccination for hepatitis B.<\/td>\n<td>No, but response to hepatitis C treatment is stronger<\/td>\n<\/tr>\n<tr>\n<td>TB (lungs)<\/td>\n<td>500 or less<\/td>\n<td>No*<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Candida and other skin problems. Herpes<\/td>\n<td>300 or less<\/td>\n<td>No*<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Gut infections: giardia, cryptosporidia, microsporidia<\/td>\n<td>300 or less<\/td>\n<td>None, care with food and water etc<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Wasting syndrome<\/td>\n<td>300 or less usually<\/td>\n<td>None<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>PCP<\/td>\n<td>200 or less<\/td>\n<td>Yes<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Toxoplasmosis<\/td>\n<td>200 or less<\/td>\n<td>Yes<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Cryptococcal meningitis<\/td>\n<td>100 or less<\/td>\n<td>Sometimes*<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>MAI\/MAC<\/td>\n<td>100 or less<\/td>\n<td>No*<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>CMV<\/td>\n<td>50 or less<\/td>\n<td>No*<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>* Drugs can be used for prophylaxis, but risks of side effects and developing resistance usually outweight benefits of protection.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This table summarises the OIs and coinfections discussed in section 5, together with the impact of ARV treatment. Table: OIs and coinfections and the impact of ARVs Opportunistic infection CD4 risk level (cells\/mm3) Prophylaxis Protection returns after ARVs increase CD4 &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":315,"menu_order":6,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-333","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/pages\/333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/comments?post=333"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/pages\/333\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/pages\/315"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/ttfa\/wp-json\/wp\/v2\/media?parent=333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}